BioTheranostics this week announced the appointment of Michael Dugan as its new chief medical officer and Catherine Schnabel as its VP of medical, clinical, and regulatory affairs.

Dugan was previously VP and chief medical officer at Roche Molecular Systems. Schnabel joined BioTheranostics in 2009. Previously she handled medical affairs at Amylin Pharmaceuticals and held research roles at Genoptix and Genentech.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.